Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
复制标题
DOI：
10.1038/sj.bjc.6601158
复制
发表时间：
2003-08-18
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
铼-188-HEDP（188 Re-HEDP）是一种治疗转移性骨痛的新型放射性药物。作为188 W/188 Re发生器的产物，其物理半衰期短，仅为16.9h，最大β能量为2.1MeV，便于临床治疗使用。我们观察了27例前列腺癌骨转移患者应用188 Re-HEDP治疗后的镇痛效果、镇痛药摄入量和骨髓功能损害。所有患者在治疗前和治疗后12周接受了一组标准化问题的采访。188 Re-HEDP剂量2700-3459 MBq。每周采集血样，持续12周，并进行血细胞计数。患者描述了治疗后12周Karnofsky行为量表的改善，从74± 7%改善至85±9%（P= 0. 001）。疼痛评分在治疗后第3 ~ 8周从44±18降至27±20%（P=0.009）。76%的患者描述了疼痛缓解，而没有增加止痛剂的摄入。20%的患者可以停止使用止痛药，并且没有疼痛。治疗后第2 ~ 4周平均血小板计数从（286±75）*103 μ l−1降至（215±92）*103 μl−1，平均白细胞计数从（7.7±1.5）*103 μl−1降至（6.0±1.9）*103 μl−1。治疗前后血小板和白细胞的最大值差异无统计学意义（P=0.021和0.094）。总之，188 Re-HEDP是一种有效的放射性药物，用于姑息治疗前列腺癌转移性骨痛，并显示出最小的骨髓毒性。
Rhenium-188-HEDP (188Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain. As a product of 188W/188Re generator, it is convenient for clinical therapeutic use with a short physical half-life of 16.9 h and a maximal β-energy of 2.1 MeV. We investigated the effect of 188Re-HEDP on pain relief, analgesic intake and impairment of bone marrow function in 27 patients with bone metastases induced from prostate cancer. All patients were interviewed using a standardised set of questions before, and after therapy for 12 weeks. The patients were treated with 2700–3459 MBq of 188Re-HEDP. Blood samples were taken weekly for 12 weeks, and a blood count was performed. Patients described an improvement on the Karnofsky performance scale from 74±7 to 85±9% 12 weeks after therapy (P=0.001). The pain score showed a maximum decrease from 44±18 to 27±20% in the third to the eight week after therapy (P=0.009). Seventy-six percent of the patients described a pain relief without increase of analgesic intake. Twenty percent of the patients could discontinue their analgesics and were pain free. Mean platelet count decreased from (286±75)*103 μl−1 to (215±92)*103 μl−1, and mean leucocyte count from (7.7±1.5)*103 μl−1 to (6.0±1.9)*103 μl−1 in the second to the fourth week after therapy. The maximal differences between the values of platelets and leucocytes before and after therapy were not statistically significant (P=0.021 and 0.094). In conclusion, 188Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain in prostate cancer and shows minimal bone marrow toxicity.
登录
查看更多内容
DOI：
10.1007/s002590000315
发表时间：
2000-10-01
期刊：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
影响因子：
--
作者：
Kraeber-Bodéré, F;Campion, L;Resche, I
通讯作者：
Resche, I
影响因子：
10.6
作者：
Liepe, K;Kropp, J;Franke, WG
通讯作者：
Franke, WG
影响因子：
3.4
作者：
McEwan, AJB
通讯作者：
McEwan, AJB
DOI：
10.1007/s002590050017
发表时间：
2000-02-01
期刊：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
影响因子：
--
作者：
Palmedo, H;Guhlke, S;Biersack, HJ
通讯作者：
Biersack, HJ
DOI：
10.1007/bf00841394
发表时间：
1997-06-01
期刊：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
影响因子：
--
作者：
Lin, WY;Lin, CP;Stabin, MF
通讯作者：
Stabin, MF